SLG
ARRY

Stanley-Laman Group’s Array Biopharma Inc ARRY Stock Holding History

Stanley-Laman Group’s Portfolio ARRY Stock Details ARRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-52,187
Closed -$876K – 239
2018
Q2 		$876K Buy
+52,187
New +$830K 0.2% 151

Other funds holding ARRY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Stanley-Laman Group's ARRY Position: Q3 2018 in Review

Stanley-Laman Group sold out of Array Biopharma Inc (ARRY) in Q3 2018, closing a stake of 52,187 shares — an estimated $876K sold.

Stanley-Laman Group first reported a position in ARRY in Q2 2018 and held it in 1 quarter. The position peaked at $876K in Q2 2018. 208 funds tracked by Wall St. Rank hold ARRY as of Q3 2018.

  • Stanley-Laman Group reported no remaining Array Biopharma Inc position as of Q3 2018 after selling out during the quarter.
  • Stanley-Laman Group sold 52,187 Array Biopharma Inc shares in Q3 2018, an estimated $876K.
  • Stanley-Laman Group first reported a position in Array Biopharma Inc in Q2 2018 and held it in 1 quarter.
  • Stanley-Laman Group's Array Biopharma Inc position peaked at $876K in Q2 2018.
  • 208 funds tracked by Wall St. Rank held Array Biopharma Inc as of Q3 2018.

Based on Stanley-Laman Group's 13F filing for Q3 2018, filed 30 Oct 2018.